Effect of supplementation in treatment of pregnancy complications
Phase 3
- Conditions
- Sequelae of complication of pregnancy, childbirth and the puerperiumPregnancy.
- Registration Number
- IRCT201410035623N27
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Pregnant women primigravida
Aged 18-40 years old
At risk for pre-eclampsia
Exclusion Criteria
Unable or unwilling to give written informed consent
Abnormal fetal anomaly scan
Treated with warfarin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pre-eclampsia rate. Timepoint: After delivery. Method of measurement: Medical record.;Low birth weight (LBW) (<2500 g). Timepoint: After delivery. Method of measurement: Scale.;Newborn's birth size. Timepoint: After delivery. Method of measurement: Scale and tape.;Preterm delivery (<37 weeks). Timepoint: After delivery. Method of measurement: Medical record.
- Secondary Outcome Measures
Name Time Method Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Eliza.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Eliza.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Triglyceride. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Blood pressures. Timepoint: Baseline and End-of-trial. Method of measurement: Manometer.